EASD 2022: Semaglutide Treatment for Overweight/Obesity Reduces 10-Year Risk of Developing Type 2 Diabetes
Effects were most pronounced among those at highest risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.